Case Report: Immune Checkpoint Inhibitors Successfully Controlled Asymptomatic Brain Metastasis in Esophageal Squamous Cell Carcinoma

Front Immunol. 2022 Mar 1:13:746869. doi: 10.3389/fimmu.2022.746869. eCollection 2022.

Abstract

Background: Brain metastases are the most common cause of intracranial malignancy, often resulting in significant morbidity and mortality. Brain metastases from esophageal squamous cell carcinoma (ESCC) are relatively rare, with a rate of generally less than 2%.

Case report: In this article, we report a rare case of ESCC with asymptomatic brain metastasis. The combined positive score (CPS) of programmed cell death-ligand 1 (PD-L1) from the primary tumor was 2 by DAKO 22C3 and 3 by VENTANA SP263. The proportion of tumor infiltrating lymphocytes (TILs) was 1%. After receiving 15 cycles of immune checkpoint inhibitors (ICIs), the patient's brain metastatic lesion had disappeared and was replaced by a local necrotic area. He retains good cognitive function with a stable disease at the primary site.

Conclusions: This is the first to be reported in an ESCC patient whose brain metastatic lesion had a complete response to ICIs, which may provide supporting data for using ICIs as an option of treatment for ESCC patients with brain metastases.

Keywords: PD-L1; brain metastasis; esophageal carcinoma; esophageal squamous cell carcinoma; immune checkpoint inhibitors.

Publication types

  • Case Reports

MeSH terms

  • B7-H1 Antigen / metabolism
  • Brain Neoplasms* / drug therapy
  • Esophageal Neoplasms* / pathology
  • Esophageal Squamous Cell Carcinoma* / drug therapy
  • Esophageal Squamous Cell Carcinoma* / pathology
  • Humans
  • Immune Checkpoint Inhibitors
  • Male

Substances

  • B7-H1 Antigen
  • Immune Checkpoint Inhibitors